Logo image
Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions
期刊文章   同儕審查

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions

Hung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, Tsai-Sheng Yang, John Wen-Cheng Chang, Chia-Hsun Hsieh, Shuen-Iu Hung, Chun-Wei Lu, Jen-Shi Chen, Wen-Chi Chou, …
Allergology international, 卷.73(4), 頁碼.580-586
01/10/2024
PMID: 38594174
Web of Science ID: WOS:001319736600001

摘要

Adverse drug reactions Anaphylaxis Biomarker Drug hypersensitivity HLA
Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock. There is no method to predict or prevent ADRs caused by oxaliplatin. Therefore, we aimed to investigate the genetic HLA predisposition and immune mechanism of oxaliplatin-induced ADRs. A retrospective review was performed for 154 patients with ADRs induced by oxaliplatin during 2016–2021 recorded in our ADR notification system. HLA genotyping was conducted for 47 patients with oxaliplatin-induced ADRs, 1100 general population controls, and 34 oxaliplatin-tolerant controls in 2019–2023. The in vitro basophil activation test (BAT) was performed and oxaliplatin-specific IgE levels were determined. The incidence of oxaliplatin-induced ADRs and anaphylactic shock in our cohort was 7.1% and 0.15%, respectively. Of the 154 patients, 67.5% suffered rash/eruption; 26.0% of the patients who could not undergo oxaliplatin rechallenge were considered to show oxaliplatin-induced immune-mediated hypersensitivity reactions (HRs). The genetic study found that the HLA-DRB∗12:01 allele was associated with oxaliplatin-induced HRs compared to the general population controls (sensitivity = 42.9%; odds ratio [OR] = 3.4; 95% CI = 1.4–8.2; P = 0.008) and tolerant controls (OR = 12; 95% CI = 2.3–63.7; P = 0.001). The in vitro BAT showed higher activation of CD63+ basophils in patients with oxaliplatin-induced HRs compared to the tolerant controls (P < 0.05). Only four patients (8.5%) with oxaliplatin-induced ADRs were positive for oxaliplatin-specific IgE. This study found that 26.0% of patients with oxaliplatin-induced ADRs could not undergo oxaliplatin rechallenge. HLA-DRB∗12:01 is regarded as a genetic marker for oxaliplatin-induced hypersensitivity.

檔案與連結 (1)

url
https://doi.org/10.1016/j.alit.2024.03.003檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image